These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3366218)

  • 1. Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas.
    Martinsson U; Glimelius B; Hagberg H; Sundström C
    Eur J Haematol; 1988 Apr; 40(4):289-98. PubMed ID: 3366218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primarily asymptomatic low-grade non-Hodgkin lymphomas: prediction of symptom-free survival and total survival.
    Martinsson U; Glimelius B; Hagberg H; Sundström C
    Eur J Haematol; 1989 Oct; 43(4):332-8. PubMed ID: 2583259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.
    Hagberg H; Glimelius B; Gronowitz S; Killander A; Källander C; Schröder T
    Scand J Haematol; 1984 Jul; 33(1):59-67. PubMed ID: 6379852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
    Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
    Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
    Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
    Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of serum lactic dehydrogenase levels and fraction of S-phase cells in non-Hodgkin lymphomas.
    Lindh J; Lenner P; Osterman B; Roos G
    Eur J Haematol; 1993 May; 50(5):258-63. PubMed ID: 8319787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers.
    Christiansen I; Gidlof C; Kälkner K M; Hagberg H; Bennmarker H; Tötterman T
    Br J Haematol; 1996 Mar; 92(3):639-46. PubMed ID: 8616029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
    Rehn S; Gronowitz JS; Källander C; Sundström C; Glimelius B
    Br J Cancer; 1995 May; 71(5):1099-105. PubMed ID: 7734308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic significance of the histological classification and staging for patients with a malignant non-Hodgkin lymphoma].
    Raemaekers JM; Snoeijen JJ; Bogman MJ; Rutten E; Strijk SP; Manni JJ
    Ned Tijdschr Geneeskd; 1993 Apr; 137(16):815-20. PubMed ID: 8487885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma.
    Rehn S; Glimelius B; Strang P; Sundström C; Tribukait B
    Hematol Oncol; 1990; 8(1):1-12. PubMed ID: 2298418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers.
    Gronowitz JS; Steinholtz L; Källander CF; Hagberg H; Bergh J
    Cancer; 1986 Jul; 58(1):111-8. PubMed ID: 3011236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma.
    Rehn S; Glimelius B; Sundström C
    Hematol Oncol; 1991; 9(6):287-98. PubMed ID: 1748395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients].
    García Zueco JC; Delgado MP; Giraldo MP; Perella M; Rubio-Félix D; Giralt M
    Sangre (Barc); 1992 Oct; 37(5):337-44. PubMed ID: 1293772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
    Heinz R; Hanak H; Stacher A
    Klin Wochenschr; 1985 Jul; 63(14):619-26. PubMed ID: 3839867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic parameters in low-grade non-Hodgkin's lymphomas.
    Zemunik T; Vucković J; Forenpoher G; Knezević N; Stula N; Dubravcić M; Ribicić I; Rozga A
    Neoplasma; 1997; 44(1):13-7. PubMed ID: 9201275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chlorambucil, vincristine and cytarabine (COA) treatment of low grade lymphomas.
    Iaffaioli RV; Frasci G; Palmieri G; Tagliaferri P; Montesarchio V; Pagliarulo C; Tortoriello A; Facchini G; Matano E; Lauria R
    Leuk Lymphoma; 1995 Mar; 17(1-2):147-53. PubMed ID: 7773152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis.
    Akerman M; Brandt L; Johnson A; Olsson H
    Br J Cancer; 1987 Feb; 55(2):219-23. PubMed ID: 3814492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
    Cowan RA; Jones M; Harris M; Steward WP; Radford JA; Wagstaff J; Deakin DP; Crowther D
    Br J Cancer; 1989 Feb; 59(2):276-82. PubMed ID: 2930692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.